KYMR
Kymera Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
119.80
▼ 1.70 (1.40%)
MARKET · —
Price
Open
121.80
Prev close
121.50
Day high
125.71
Day low
119.78
Volume
497.30K
Market cap
$9.85B
P/E (TTM)
—
52W range
39.84 – 130.05
Trailing performance
Returnvs SPY
1W
+2.05%
+3.4%
1M
+8.53%
+4.8%
3M
+48.62%
+45.5%
6M
+37.07%
+26.0%
YTD
+53.96%
+41.7%
1Y
+182.88%
+162.9%
3Y
+522.01%
+447.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$9.85B
Enterprise value$9.35B
Revenue (TTM)$105.00M
Gross profit$-270.57M
EBITDA$-339.89M
Net income$-299.60M
EPS (TTM)$-3.20
Free cash flow$-144.07M
Total cash$690.99M
Total debt$78.56M
Book value / share$18.23
Shares outstanding82.26M
Float66.06M
Short % of float15.44%
Dividend yield—
Beta (5Y)1.95
Valuation & profitability ratios
Trailing P/E—
Forward P/E-24.16
PEG ratio—
Price / sales—
Price / book6.57
EV / revenue89.04
EV / EBITDA-27.51
Gross margin-257.69%
Operating margin-116.32%
Profit margin-285.33%
Return on equity-24.15%
Return on assets-15.59%
Debt / equity5.21
Current ratio10.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $39.21M | $47.07M | $78.59M | $46.83M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$311.35M | -$223.86M | -$146.96M | -$154.81M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$311.35M | -$223.86M | -$146.96M | -$154.81M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.74 | -0.62 | +16.0% |
| Mar 2026 | -0.86 | -0.71 | +17.1% |
| Dec 2025 | -0.77 | -0.98 | -27.1% |
| Sep 2025 | -0.78 | -0.94 | -20.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.24 | 20 | $3.57M | +29.3% |
| Next quarter | -1.26 | 19 | $3.86M | +34.6% |
| Current year | -3.80 | 20 | $106.18M | +170.8% |
| Next year | -4.96 | 20 | $45.20M | -57.4% |
Analyst targets & ownership
Mean target$130.91
High target$155.00
Low target$111.00
Implied upside9.27%
Analyst count22
ConsensusSTRONG BUY
Strong buy / Buy4 / 17
Hold3
Sell / Strong sell0 / 0
Held by insiders2.12%
Held by institutions117.09%
Institutions holding390
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-1.59M
Net selling
Buy transactions
25
564.97K shares
Sell transactions
23
2.15M shares
Net transactions
+48
Buys less sells
Sell : buy shares
3.8 : 1
Mixed
Insider-held shares
1.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 27, 26 | ROONEY TERENCE Officer |
STOCK | 38.00K | $0 | Direct |
| Jul 7, 26 | MAINOLFI NELLO Chief Executive Officer |
SELL | 50.00K | $5.95M | Direct |
| Jul 7, 26 | MAINOLFI NELLO Chief Executive Officer |
CONVERSION | 50.00K | $104.00K | Direct |
| Jul 1, 26 | MAINOLFI NELLO Chief Executive Officer |
SELL | 80.00K | $9.22M | Direct |
| Jul 1, 26 | GOODMAN NOAH Officer |
SELL | 3.39K | $387.33K | Direct |
| Jul 1, 26 | MAINOLFI NELLO Chief Executive Officer |
CONVERSION | 80.00K | $166.40K | Direct |
| Jun 30, 26 | JACOBS BRUCE N. Chief Financial Officer |
SELL | 77.11K | $8.86M | Direct |
| Jun 30, 26 | JACOBS BRUCE N. Chief Financial Officer |
CONVERSION | 61.38K | $327.14K | Direct |
| Jun 26, 26 | BVF PARTNERS L.P. Affiliated Person |
SELL | 1.63M | $173.67M | Indirect |
| Jun 25, 26 | GOODMAN NOAH Officer |
SELL | 5.00K | $570.00K | Direct |
| Jun 25, 26 | GOODMAN NOAH Officer |
CONVERSION | 5.00K | $105.25K | Direct |
| Jun 22, 26 | GOODMAN NOAH Officer |
SELL | 2.50K | $247.50K | Direct |
| Jun 22, 26 | GOODMAN NOAH Officer |
CONVERSION | 2.50K | $52.63K | Direct |
| Jun 2, 26 | JACOBS BRUCE N. Chief Financial Officer |
CONVERSION | 12.65K | $26.32K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS BRIAN R |
Officer | 56.63K | Stock Award(Grant) |
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BVF PARTNERS L P |
Affiliated Person | — | Purchase |
BVF PARTNERS L.P. |
Affiliated Person | — | Sale |
CHADWICK JEREMY G |
Chief Operating Officer | 44.02K | Sale |
CHINIARA ELLEN V |
Officer | 80.08K | Stock Award(Grant) |
GOLLOB JARED AUGUST |
Officer | 117.13K | Sale |
GOODMAN NOAH |
Officer | 47.18K | Sale |
JACOBS BRUCE N. |
Chief Financial Officer | 244.88K | Sale |
MAINOLFI NELLO |
Chief Executive Officer | 666.57K | Sale |
Moving averages & technicals
SMA 10
117.54
+1.92% from price
SMA 20
111.57
+7.38% from price
SMA 50
108.73
+10.18% from price
SMA 100
95.78
+25.08% from price
SMA 200
86.18
+39.02% from price
EMA 12
117.13
+2.28% from price
EMA 26
112.98
+6.03% from price
EMA 50
107.50
+11.45% from price
RSI (14)
60.3
Neutral
MACD (12,26,9)
4.14
Hist 1.18
ATR (14)
4.76
3.98% of price
Realised vol 30D
44.5%
Annualised
Bollinger upper
126.31
20, 2σ
Bollinger lower
96.84
20, 2σ
50 / 200 cross
Golden
108.73 vs 86.18
Trend bias
Above 200
+39.02%
Risk profile
Beta vs SPY
0.92
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
44.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.7%
Peak to trough
Max drawdown 5Y
-83.5%
Peak to trough
ATR 14
4.76
3.98% of price
Beta (reported)
1.95
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.48
Positioning, not flow
Max pain
95.00
-20.7% from spot
ATM implied vol
54.4%
Nearest strike to spot
Skew (10% OTM)
-4.0%
Calls bid over puts
Call volume
37
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
120.00
36 contracts
Heaviest put OI
95.00
40 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
MT Newswires · 12d ago
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Zacks · 16d ago
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)
Simply Wall St. · 16d ago
Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 17d ago
Kymera Therapeutics Q2 Earnings Call Highlights
MarketBeat · 17d ago
Kymera Therapeutics Q2 Net Loss Narrows, Collaboration Revenue Rises
MT Newswires · 17d ago
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.